Shares of biopharmaceutical company PDS Biotechnology (NASDAQ:PDSB) are on the rise today after it announced interim data from a Phase 2 study evaluating the combination of PDS0101 and Merck’s (NYSE:MRK) Keutruda for the treatment of HPV-16 positive head and neck squamous cell carcinoma (HNSCC) patients.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
In the study, the drug combination was observed to be well tolerated and had an overall survival rate of 87.1% at 12 months. Further, median progression-free survival was 10.4 months alongside a disease control rate of 70.6%.
Importantly, the findings support a global confirmatory study and the company is now planning to initiate the trial this year.
After rising nearly 35% over the past year, PDSB shares are up a further 28% at the time of writing today.
Read full Disclosure
